Livanova PLC current report, 30 April 2018

Full document

LivaNova PLC Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by LivaNova PLC on April 30, 2018. The report details the completion of a significant asset disposition involving the company's Cardiac Rhythm Management (CRM) business franchise.

Key Financial Metrics

  • Transaction Value: The CRM Sale closed for a purchase price of approximately $197.3 million, including customary closing adjustments.
  • Indemnity Liability: The Company agreed to provide a limited indemnity to the purchasers of up to €16.5 million related to an ongoing antitrust investigation in France.
  • Other Metrics: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity for the reporting period.

Material Changes

The primary material change is the divestiture of the CRM business franchise to MicroPort Cardiac Rhythm B.V. and MicroPort Scientific Corporation. This transaction represents a strategic shift in the company's portfolio, removing the CRM segment from LivaNova's operations as of the closing date.

Outlook, Risks, and Contingencies

  • Antitrust Investigation: A regional antitrust authority in France initiated an investigation into the French cardiac rhythm management market prior to the closing. A subsidiary of the CRM business in Clamart, France, is under investigation. The subsidiary asserts full compliance and intends to cooperate.
  • Forward-Looking Statements: The filing includes standard cautionary language regarding risks and uncertainties, including unexpected costs or liabilities arising from the sale of the CRM business.
  • Management Commentary: The Company issued a press release on April 30, 2018, announcing the closing of the sale.

Investor Verification Checklist

  • Verify the final purchase price of $197.3 million and any subsequent closing adjustments.
  • Confirm the status of the French antitrust investigation and the potential impact of the €16.5 million indemnity cap.
  • Review the Stock and Asset Purchase Agreement (Exhibit 2.01) for specific terms regarding retained liabilities.
  • Assess the impact of the CRM divestiture on LivaNova's remaining revenue streams and future growth strategy.